The Quiet Consolidation Nobody Is Talking About
Regional pharmacy benefit managers – the mid-sized PBMs that have long served employer health plans, union trusts, and regional insurers – are disappearing. Not through bankruptcy or regulatory shutdown, but through a steady stream of acquisitions flowing toward Express Scripts, the PBM giant owned by Cigna’s Evernorth division. The deals are being structured quietly, announced in brief press releases if at all, and closed with terms that rarely become public.
This is not a sudden trend. It has been building for years, accelerating as smaller PBMs face a pricing environment that increasingly favors scale. What makes the current moment distinct is the pace – and the fact that the targets being absorbed are no longer the tiny, single-state operators. Regional PBMs managing drug benefits for hundreds of thousands of covered lives are now in play.
The independent PBM sector is contracting faster than most employer plan sponsors realize.
Why Regional PBMs Are Selling Now
The economics of running a mid-sized PBM have grown structurally difficult. Pharmaceutical manufacturers have narrowed the spread between wholesale acquisition cost and what PBMs can retain as rebate revenue, squeezing the margin that historically kept independent operators viable. At the same time, drug pricing transparency regulations at both the federal and state level are stripping away the pricing flexibility that smaller PBMs relied on to compete without matching the volume advantages of their larger rivals.
Express Scripts can negotiate directly with manufacturers at a scale that a regional PBM serving, say, a single-state Medicaid managed care plan or a cluster of municipal employers simply cannot match. That gap in negotiating leverage translates directly into formulary outcomes – which drugs get covered at what tier, and at what cost to the plan. When employer clients begin comparing formulary performance benchmarks, the smaller PBM is often losing the conversation before price is even discussed.
There is also a technology pressure. Modern PBM operations require clinical decision support tools, real-time drug utilization review systems, and specialty pharmacy integration platforms that carry significant development and maintenance costs. Smaller operators who built their infrastructure a decade ago are now running on systems that cannot easily support the biosimilar management workflows or the GLP-1 utilization controls that employer clients are actively demanding. Selling to Express Scripts transfers that technology burden while delivering the ownership group a clean exit.
What Express Scripts Gets – and What Employers Lose
For Express Scripts, each regional acquisition is a straightforward play for covered lives. Every plan member absorbed from a regional PBM feeds volume into Express Scripts’ existing rebate contracts, improving per-unit economics across the entire book of business. The acquisition cost is often recovered quickly because the acquired lives immediately contribute to rebate tiers that the regional PBM was nowhere near achieving on its own. The acquired company’s administrative infrastructure is typically rationalized within 18 to 24 months, meaning most of the cost structure gets eliminated while the revenue remains.
Employer plan sponsors are in a more complicated position. Many of them chose a regional PBM specifically to avoid the opacity that has long characterized the large national PBMs. Regional operators built their client relationships on accessibility – a plan administrator could actually reach a clinical account manager, get a real answer about a formulary exception, or negotiate a custom plan design without being handed a standardized product tier. That service model does not survive the acquisition intact. Post-close, the plan typically migrates onto Express Scripts’ standard platform, with pricing and formulary structures dictated by Evernorth’s commercial framework rather than anything negotiated locally.
The consolidation also narrows the competitive market for employers shopping for PBM contracts. When a regional operator that served as a credible alternative to Express Scripts, CVS Caremark, and OptumRx disappears, the bidding pool shrinks. Employers who relied on the regional PBM’s presence to keep the national giants honest during renewal negotiations lose that leverage. This dynamic – fewer credible bidders producing less competitive pressure on pricing – is repeating across local markets every time another regional deal closes. The pattern is similar to what has played out in other healthcare services sectors, including regional psychiatric staffing, where consolidation has steadily reduced the number of independent operators able to compete against scaled national entities.
The View From Here
There is no regulatory mechanism currently positioned to slow this consolidation in any meaningful way. The Federal Trade Commission has signaled heightened scrutiny of healthcare mergers, but PBM acquisitions at the regional level rarely trigger the revenue thresholds that bring automatic antitrust review – and even when they do, the structural harm to local employer markets is notoriously difficult to quantify in the framework regulators use to evaluate competitive injury. Express Scripts will keep buying, and the question for employer plan sponsors is not whether the regional PBM market will consolidate further, but whether they will notice until the alternatives are simply gone.
